⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
TLRY
TAK
TNDM
NVS
BMY
PFE
INCY
JNJ
AZN
MRK
ABBV
CRSP
SCLX
RIGL
JAZZ
GILD
REGN
AMGN
BIIB
PTGX
EXAS
SNOW
SRPT
VRTX
BNTX
ALKS
RGEN
IMUX
ADPT
ATRC
CRNX
CYTK
DTIL
EXEL
FGEN
GALT
GNTX
GRFS
GSK
HRMY
IDXX
ILMN
INSM
IONS
IRWD
KODK
LAKE
LULU
LYFT
MAR
MDLZ
MELI
MIRM
MNKD
MRNA
MTCH
NBIX
NCLH
NEM
NTRA
NVCR
ODFL
OMER
ORGO
OTEX
PACB
PBYI
PCAR
PEGA
PERI
PETS
PLRX
PMVP
PPC
PRGS
PRTA
PSNL
PTN
PZZA
QGEN
QTRX
RARE
RCEL
RDHL
RLAY
RLGT
RMD
ROST
RRX
RYAAY
RYTM
SAN
SBAC
SBRA
SEIC
SIGA
SIRI
SITE
SLAB
SLGN
SMCI
SMMT
SNPS
SNY
SOFI
SONO
SPCE
SSYS
STNG
STRA
STRL
STX
SWKS
SYK
SYNA
TCOM
TDOC
TECK
TEVA
TFX
TGTX
TIGR
TRMB
TRVG
TTWO
TUSK
TXRH
ULTA
UMC
UNFI
UNH
URBN
UTHR
VEEV
VELO
VERU
VIVO
VKTX
VLRS
VNDA
VRSK
VSAT
VTGN
WDC
WEC
WERN
WGO
WIX
WMB
WST
WTW
WYNN
XOM
XPER
XPO
XRAY
YETI
YRD
YUM
ZBRA
ZLAB
ZYME
Form 8-K
sec.gov
IONS
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
businesswire.com
IONS
Form 8-K
sec.gov
IONS
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy
globenewswire.com
NTLA
REGN
ALNY
IONS
PFE
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
businesswire.com
IONS
One Month Remains to Submit for 3rd Annual ATTR Early-Career Research Forum; Two $100,000 Wiesman Awards to Be Granted
prnewswire.com
AZN
IONS
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB
globenewswire.com
AMGN
CSL
NVS
REGN
SNY
UCB
AZN
IONS
TEVA
Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
ASMB
IONS
BIIB
ALT
TEVA
ANVS
SUPN
ABBV
AVXL
MRK
KAR
VNDA
Global RNAi Technology Market is Expected to Showcase Significant Growth at a CAGR of ~14% by 2034 | DelveInsight
globenewswire.com
BNTX
MRNA
DVAX
ALNY
BIIB
IONS
ARCT
VRTX
PFE
SGMO
AZN
CAT
TMO
LH